Cortechs.ai | Emerson Hospital Selects NeuroQuant for Quantifying Brain Volume Loss in TBI patients at the Dr. Robert C. Cantu Concussion Center

Emerson Hospital Selects NeuroQuant for Quantifying Brain Volume Loss in TBI patients at the Dr. Robert C. Cantu Concussion Center

Cortechs.ai’ NeuroQuant provides valuable information to Boston area neurologists and radiologists in the assessment of TBI.

(San Diego, CA) October 13, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that NeuroQuant® was chosen by the physicians who support the Dr. Robert C. Cantu Concussion Center at Emerson Hospital to help accurately quantify brain volume loss in athletes who suffer repetitive concussions and other types of traumatic brain injuries. The Dr. Robert C. Cantu Concussion Center provides service to patients served by Emerson Hospital in Concord, Massachusetts and the 25 towns in the hospital’s service area.

NeuroQuant provides automatic, accurate and consistent measurements of brain structures from 3D T1 MRI images, allowing neurologists and radiologists to easily review, assess, quantify and monitor brain volume loss and its changes over time, as compared to normative values.

“We are excited to work with Cortechs.ai and use NeuroQuant for the assessment of brain volumes in patients suffering sports related trauma,” commented Dr. Robert Cantu, Chief of Neurosurgery Service and Director of Sports Medicine at Emerson Hospital. “A thorough evaluation of my patients suffering concussions or other brain trauma is of the foremost importance, and with NeuroQuant we get a better insight into specific brain structures, as well as, the whole brain.”

“For many brain disorders, including Alzheimer’s disease, epilepsy, multiple sclerosis, traumatic brain injury, NeuroQuant provides physicians an accurate measurement solution that provides objective evidence of neurodegeneration,” said Guri Stark, Cortechs.ai’ CEO. “Assessing the impact of repeat concussions on brain structures has been an important focus area for Cortechs.ai, and we are very pleased that Emerson Hospital recognized the benefits of using NeuroQuant in their concussion centers.”

About the Dr. Robert C. Cantu Concussion Center
The Dr. Robert C. Cantu Concussion Center at Emerson Hospital in Concord, Mass. combines the expertise of one of the country’s leading concussion experts with the latest therapies for the diagnosis, treatment, and management of all types of concussive brain injuries. Expert and comprehensive evaluation and treatment are available to athletes and others suffering from all types of concussive injuries.

About Cortechs.ai

Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.  As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai for further information.

Media Contact:
Stephanie Harrison
Cortechs.ai, Inc.
+1 858 459-9700

More Resources

04/10/2026

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate delivers consistent, reliable AI-powered prostate MRI insights across vendors, ensuring confident diagnosis and streamlined clinical workflows.

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.
Scroll to Top